Product Images Rexulti

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 19 images provide visual information about the product associated with Rexulti NDC 59148-039 by Otsuka America Pharmaceutical, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

rexulti 025mg bottle label

rexulti 025mg carton

rexulti 05mg bottle label

rexulti 05mg carton

rexulti 1mg bottle label

rexulti 1mg carton

This text seems to be a description of a medication called "REXULTI." It includes the tablet size (30 tablets) and the national drug code (NDC 59145-037-13). The medication contains brexpiprazole, which is a type of drug used to treat certain mental illnesses. The rest of the text appears to be gibberish or random letters/words and cannot be understood.*

rexulti 2mg bottle label

rexulti 2mg carton

The text appears to be a mix of random letters, symbols, and numbers. There is no readable description available.*

rexulti 3mg bottle label

rexulti 3mg carton

REXULTI is a prescription medication containing 30 tablets of Brexpiprazole, used for treating certain mental disorders. The tablets are white, oval-shaped, with NDC code 5914303913 or 5914803913. The medication guide outlines the uses, dosage, and possible side effects. It is essential to consult a physician before taking the medication.*

rexulti 4mg bottle label

rexulti 4mg carton

rexulti chem structure

rexulti figure 01

This appears to be a report on Brexpiprazole PK, with information related to measures of Fold Change, 90% confidence intervals, and impairment of renal and hepatic systems. It also includes population descriptions based on gender and age, as well as a chart showing changes relative to reference.*

rexulti figure 02

Brexpiprazole PK was analyzed for its change due to measures fold change and 90% confidence intervals caused by different inhibitors and inducers of CYP enzymes, such as CYP3A4 inhibitor Crmex, CYP2D6 inhibitor Cmex1o, CYP3A4 Inducer Crmex-, CYP2BS inhibitor Cmax, Gastric PH increase caused by Omeprazole, and others. The change was observed relative to the reference (without interacting drug).*

rexulti figure 03

This text appears to be a chart showing the effect of certain substances on various substrates and analytes. It includes the substrates Dextromethorphan, Fexofenadine, Bupropion, Lovastatin, and Roswastatin and notes their PK fold changes and confidence intervals for measurements of analytes in urine. Without more context, it is unclear what the purpose of this information is or how it might be used.*

rexulti figure 04

rexulti figure 05

rexulti figure 06

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.

Table of Contents